Industry News: Real-World Evidence from Mobile Devices, the Opioid Crisis, & More
September, 2020Keeping up with what’s going on in the industry can be a bit of a headache; there are new studies coming out every day and new initiatives launching all the time. Don’t stress, we’ve neatly chunked together 3 of the most interesting and useful stories from the last month – so you don’t have to! This month we take a look at the five recommendations made for the clinical trials industry around using mobile health apps and devices as a method for outcome data collection. We also hear how evidence about effectiveness gathered from the real world could offer new hope for reversing the opioid crisis. Lastly, we finish with Real-World Evidence presented by Teva Pharmaceuticals.
Report: Five ways to bolster real-world evidence from mobile devices
By Jonah Comstock for MobiHealthNews
One of the biggest promises of mobile health apps and wearables is the sheer amount of data they collect. As that dataset grows, a number of different stakeholders are taking an interest in it, among them patients themselves, doctors, and clinical researchers. The latter is the focus of a new report out from the Duke-Margolis Center for Health Policy. In the report, the Center presents five recommendations for the industry around using mobile health apps and devices in clinical trials.
Teva Pharmaceuticals this month announced data from a real-world evidence study.
The data showed that in patients with asthma and chronic obstructive pulmonary disease (COPD), DuoResp Spiromax®(budesonide/formoterol fumarate dihydrate) was non-inferior to Symbicort Turbuhaler® (budesonide/formoterol fumarate dihydrate) in regards to disease control. DuoResp Spiromax® aims to reduce common inhaler errors and enhance usability for patients with asthma and COPD, delivering medication via a breath-activated, multi-dose dry powder inhaler. The study was presented at the 2017 European Respiratory Society International Congress in Milan, Italy, the largest respiratory conference in the world.
Evidence about effectiveness offers hope for reversing opioid crisis
By Joe Selby & Sherry Dubester for Morning Consult
The impact of the opioid crisis can be measured in many ways, such as the fourfold increase in the number of opioid-related deaths nationally since 1999, including more than 33,000 lives lost in 2015, or in the $42 billion in lost productivity associated with opioid use disorders. Comparative clinical effectiveness research (CER) is health research expressly aimed at answering practical, real-world questions, and it will now be used to tackle the opioid crisis. This patient-centred research aims to produce real-world evidence that is immediately relevant to those on the frontlines of the opioid crisis who are making potentially life-changing decisions about which prevention and treatment strategies to use and which policies to enact.
Follow Us
Share
More News
IgniteData secures £1/2 million Innovate UK grant for ground-breaking clinical trial data project
How EHR-to-EDC technology is sparking better collaboration in clinical trials
6 Common Data Challenges For Clinical Researchers
How to choose an EHR-to-EDC solution
Leading healthcare technology expert Steve Tolle joins IgniteData
Guest blog: Joseph Lengfellner on the challenges and solutions for clinical trials – Part 2
Guest blog: Joseph Lengfellner on the challenges and solutions for clinical trials – Part 1
How structured data is used in clinical trials
Evidence from Electronic Health Records-to-Electronic Data Capture live pilot study
IgniteData and Leading New York City Cancer Center Collaborate to Solve the Clinical Trial Data Transfer Challenge
Clinical trial data mapping explained: Mapping EHR data
Quality data and the EHR-to-EDC dream – where and why we need to focus our energies
UK clinical trials landscape: 4 big influencers
ZS’s Qin Ye on trends and driving innovation in life sciences
Meet Archer, the platform transforming EHR-to-EDC data automation